SIRT1 and ovarian cancer: <i>In vivo</i> experiments, knocking down SIRT1 can reduce the glycolysis level and angiogenesis ability of tumor tissue.<h4>Conclusion</h4>SIRT1 promotes glycolysis and angiogenesis of ovarian cancer cells by activating β-catenin/c-myc/PKM2 pathway, thus enhancing chemotherapy resistance.